metoprolol and salbutamol

Metoprolol is a cardioselective beta-1 adrenoceptor antagonist that, at higher doses, also blocks beta-2 receptors. Salbutamol is a selective beta-2 agonist used for bronchodilation. When co-administered, metoprolol may competitively antagonise salbutamol at beta-2 adrenergic receptors in the bronchial smooth muscle, reducing the bronchodilatory response. Furthermore, beta-blockade may enhance airway reactivity and precipitate bronchoconstriction, particularly in patients with reactive airways disease. The effect is pharmacodynamic, occurring at the receptor level without alteration of drug concentrations.

Patients receiving both drugs may experience a reduced therapeutic effect from salbutamol, leading to inadequate relief of bronchospasm or worsening of asthma/COPD symptoms. In susceptible individuals, beta-blockade can cause significant bronchoconstriction, which may be life-threatening in severe asthma. However, metoprolol's relative cardioselectivity may mitigate but not eliminate this risk, especially at higher doses. The interaction is clinically relevant when salbutamol is used for acute bronchodilation, and the antagonism can blunt the drug's effectiveness.

If co-prescription is necessary, use the lowest effective dose of metoprolol and consider a more cardioselective beta-blocker. Monitor respiratory function, including peak expiratory flow (PEF) or spirometry, and assess the patient's response to inhaled salbutamol. Advise patients to report any increase in shortness of breath or wheezing. In acute bronchospasm, use non-selective beta-agonists or anticholinergics may be considered. Where possible, avoid beta-blockers in patients with known asthma; if required, use cardioselective agents with caution. Regular assessment of clinical response to bronchodilators is essential.

This interaction is well-established in pharmacological and clinical literature. Beta-blockade is known to antagonise beta-2 agonist effects, and guidelines recommend caution with concurrent use in patients with airway disease. The clinical significance is based on case reports, physiological studies, and clinical experience. No specific randomised controlled trials are available for this drug pair, but the interaction is predictable from receptor pharmacology.